Bibliography
- Burke JE, Cheronis JC, Whalley ET. Bradykinin receptor antagonists. Expert Opin Ther Patents 1995;5:331-40
- Dziadulewicz EK. Non-peptide ligands for bradykinin receptors 1995 – 2004. Expert Opin Ther Patents 2005;15:829-59
- Fincham CI, Bressan A, Paris M, Bradykinin receptor antagonists – a review of the patent literature 2005 – 2008. Expert Opin Ther Patents 2009;19:919-41
- Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004;3:845-52
- Howl J, Payne SJ. Bradykinin receptors as a therapeutic target. Expert Opin Ther Targets 2003;7:277-85
- Farkas S, Eles J. The therapeutic potential of bradykinin B1 inhibitors in chronic pain. Drugs Fut 2011;36(4):301
- Chen JJ, Johnson EJ. Targeting the bradykinin B1 Receptor to reduce pain. Expert Opin Ther Targets 2007;11:21-5
- Huang H, Player MR. Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. J Med Chem 2010;53:5383-99
- Gougat J, Ferrari B, Sarran L, SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 2004;309(2):661-9
- Sanofi. Derivatives of N-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same. WO2002076964; 2002
- Feng DM, Wai JM, Kuduk SD, 2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists. Bioorg Med Chem Lett 2005;15:2385-8
- Kuduk SD, Chang RK, Ng C, Bradykinin B1 antagonists: SAR studies in the 2,3-diaminopyridne series. Bioorg Med Chem Lett 2005;15:3925-9
- Merck & Co., Inc. 2-(Biarylalkyl)amino-3-(heterobyciclycarbonylamino)-pyridine derivatives. US20040029920; 2004
- Merck & Co., Inc. 2-(Biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives. US20040034064; 2004
- Merck & Co., Inc. 2-(Biarylalkyl)amino-3-(cykloalkanoylamino)pyridine derivatives. US20040044041; 2004
- Merck & Co., Inc. 2-(Biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives. US20040063761; 2004
- Tang C, Subramanian R, Kuo Y, Bioactivation of 2,3-diaminopyridine-containing bradykininB1receptor antagonists: irreversible binding to liver microsomal proteins and formation of glutathione conjugates. Chem. Res Toxicol 2005;18:934-45
- Wood MR, Schirrippa MK, Kim JJ, Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B receptor antagonists. J Med Chem 2006;49:1231-4
- Merck & Co., Inc. N-biphenylmethyl aminocycloalkane carboxamide derivatives. WO2003065789; 2003
- Merck & Co., Inc. N-biphenylmethyl aminocycloalkane carboxamide derivatives with a substituent on the methyl useful as Bradykinin antagonists. WO2003066577; 2003
- Merck & Co., Inc. Sulfonyl substituated N-(biarylmethyl) aminocyclopropanecarboxamides. WO2005016886; 2005
- Merck & Co., Inc. Alpha-hydroxy amides as Bradykinin antagonists or Inverse agonists. WO2005063690; 2005
- Merck & Co., Inc. Amino cyclopropane carboxamide derivatives as Bradykinin antagonists. WO2005085198; 2005
- Grunenthal GMBH. Substituted sulfonamide derivatives. WO2009090054; 2009
- Grunenthal GMBH. Substituted sulfonamide derivatives. WO2009090055; 2009
- Grunenthal GMBH. Substituted sulfonamide derivatives. WO2009109364; 2009
- Grunenthal GMBH. Substituted sulfonamide derivatives. WO2009115257; 2009
- Grunenthal GMBH. Substituted sulfonamide derivatives. WO2009124733; 2009
- Grunenthal GMBH. Substituted sulfonamide derivatives. WO2009124734; 2009
- Grunenthal GMBH. Substituted sulfonamide derivatives. WO2009124746; 2009
- Grunenthal GMBH. Substituted spiroamines. WO2010049146; 2010
- Grunenthal GMBH. Substituted benzimidazoles, benzothiazoles and benzoxazoles. WO2010142402; 2010
- Grunenthal GMBH. Substituted spiro-amides as B1R modulators. WO2010089127; 2010
- Grunenthal GMBH. Substituted spiro-amide compounds. WO2010108651; 2010
- Grunenthal GMBH. Pyrimidine and triazine sulfonamide derivatives as B1 bradykinin receptor (B1R) inhibitors for treating pain. WO2010046109; 2010
- Grunenthal GMBH. Substituted disulfonamides as BR1 modulators. WO2010051977; 2010
- Grunenthal GMBH. Substituted indole compounds as bradykinin receptor 1 modulators. WO2010089084; 2010
- Grunenthal GMBH. Sulfonylated tetrahydroazolopyrazines and their use medicinal products. WO201099938; 2010
- Grunenthal GMBH. Substituted tetrahydropyrrolopyrazine derivatives. WO201202833; 2012
- Grunenthal GMBH. Substituted benzamide compounds. US20120071461; 2012
- Evotec Neurosciences GMBH. New bradykinin B1 antagonists. WO2010020556; 2010
- DSM IP Assets B.V. Sulfonamide derivatives for use in the treatment of skin conditions. WO2011000863; 2011
- Feng DM, DiPardo RM, Wai JM, A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity. Bioorg Med Chem Lett 2008;18:682
- Kuduk SD, DiPardo RM, Chang RK, Bradykinin B1 antagonists: biphenyl SAR studies in the cyclopropanecarboxamide series. Bioorg Med Chem Lett 2007;17:3608
- Jerini AG. Small molecule Bradykinin B1 antagonists. WO2009036996; 2009
- Schaudt M, Locardi E, Zischinsky G, Novel small molecule bradykinin B1 receptor antagonists. Part 1: Benzamides and semicarbazides. Bioorg Med Chem Lett 2010;20:1225-8
- Jerini AG. Small molecule Bradykinin B1 antagonists. WO2010091876; 2010
- Zischinsky G, Stragies R, Schaudt M, Novel small molecule bradykinin B1 receptor antagonists. Part 2: 5-membered diaminoheterocycles. Bioorg Med Chem Lett 2010;20:1229-32
- Schnatbaum K, Schaudt M, Stragies R, Novel small molecule bradykinin B1 receptor antagonists. Part 3: Hydroxyurea derivatives. Bioorg Med Chem Lett 2010;20:1233-6
- Boehringer Ingelheim Int. GMBH. Novel Bradykinin B1 antagonists. WO2009027450; 2009
- Boehringer Ingelheim Int. GMBH. Compounds for use as Bradykinin B1 antagonists. WO2010097373; 2010
- Boehringer Ingelheim Int. GMBH. Compounds as Bradykinin B1 antagonists. WO2010097372; 2010
- Boehringer Ingelheim Int. GMBH. Compounds for use as Bradykinin B1 antagonists. WO2010097374; 2010
- Boehringer Ingelheim Int. GMBH. Cycloalkyl amino carbonyl derivatives as Bradykinin-B1 receptor antagonists. WO2010057899; 2010
- Richter Gedeon Nyrt. Indole derivatives. WO2012059766; 2012
- Wuitschik G, Carreira EM, Wagner B, Oxetanes in drug discovery: structural and synthetic insights. J Med Chem 2010;53:3227-46
- Hoffmann LaRoche. New biarylamide derivatives. US20120165338; 2012
- Dompe SPA. 2-Aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them. WO2011051375; 2011
- Available from: http://clinicaltrials.gov/ct2/show/NCT00533403
- Available from: http://clinicaltrials.gov/ct2/show/NCT00296569
- Available from: http://clinicaltrials.gov/ct2/show/NCT00282763
- Doods H, Hauel N, Kirsten A, BI 113823, a novel B1 receptor antagonist exhibiting antinociceptive properties in inflammatory pain models. World Institute of Pain - The 6th World Congress; 4 – 6 February 2012
- Available from: http://clinicaltrials.gov/ct2/show/study/NCT01207973
- Available from: http://apps.who.int/trialsearch/trial.aspx?trialid=EUCTR2011-000931-10-HU
- Corporate communication at the Grunenthal. Available from: http://www.grunenthal.com/grt-web/Grunenthal_Group/Research_&_Development/Preclinical_R&D/NCEs_for_the_treatment_of_pain/The_Bradykinin/124700104.jsp;jsessionid=7500772FD4E4CCDCB20E9125B54AF08B.drp2
- Corporate communication at the Evotec. Available from: http://www.evotec.com/article/en/Alliances-Projects/B1-Antagonists/16/4
- Available from: http://clinicaltrials.gov/ct2/show/NCT01319487
- Corporate communication at the Sanofi. Available from: http://en.sanofi.com/events/2012_2ndQR/docs/2012-07-26_Results-Q2-2012_slides.pdf
- Dias JP, Couture R. Suppression of vascular inflammation by kinin B1 receptor antagonism in a rat model of insulin resistance. J Cardiovasc Pharmacol 2012;60:61
- Dias JP, Couture R. Blockade of kinin B(1) receptor reverses plasma fatty acids composition changes and body and tissue fat gain in a rat model of insulin resistance. Diabetes Obes Metab 2012;14:244